Is liraglutide actually inferior to newer GLP-1 drugs for weight loss?
Quick answer
Dr. Russo compares liraglutide to semaglutide and tirzepatide on two dimensions: weight loss efficacy and injection frequency. The efficacy gap is well-documented in large randomized controlled trials, with liraglutide producing roughly half the percentage weight loss of semaglutide at approved obesity doses. His recommendation to reserve liraglutide for insurance-limited patients is consistent with current clinical practice patterns, though it omits liraglutide's established cardiovascular outcomes data from the LEADER trial.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @drmichaelrusso actually say?
Dr. Russo's core argument is straightforward: liraglutide (Saxenda/Victoza) is less effective for weight loss than semaglutide or tirzepatide, requires daily injections instead of weekly ones, and is generally not worth recommending unless it's the only insurance-covered option. He calls it a fallback, not a first choice.
He frames this in the context of GLP-1 shortages pushing people toward older medications. His exact words: "there are many many better options available than the results seen with lira glutide." He does give liraglutide credit as the right call when it's "the only one they're going to cover." That nuance matters and is worth acknowledging.
This is not a fringe take. It reflects a fairly standard clinical hierarchy among GLP-1 receptor agonists. But let's look at whether the evidence actually supports it.
Does the science back this up?
Yes, mostly. The weight loss data across these three drugs is not close, and Dr. Russo is on solid ground here. The SCALE trial (Davies et al., 2015, The Lancet) showed liraglutide 3.0 mg produced roughly 8% total body weight loss at one year. Compare that to the STEP 1 trial (Wilding et al., 2021, NEJM), where semaglutide 2.4 mg produced about 14.9% weight loss. Tirzepatide's SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) pushed that further, with up to 22.5% weight loss at the highest dose.
So the gap between liraglutide and its newer competitors is real and clinically meaningful, not just statistical noise. A difference of 6-14 percentage points in body weight is the kind of thing that changes cardiovascular risk profiles, not just pants sizes.
On dosing frequency: liraglutide is indeed a daily subcutaneous injection. Semaglutide and tirzepatide are weekly. That's not a minor lifestyle difference for most patients.
What did they get wrong (or right)?
Dr. Russo got the big picture right. The effectiveness hierarchy he describes matches the clinical trial data. He also avoided overclaiming, which is more than you can say for a lot of GLP-1 content on TikTok.
A few things worth flagging, though. He doesn't mention that liraglutide has a longer real-world safety record than semaglutide and tirzepatide. Liraglutide has been on the market since 2010 for type 2 diabetes and 2014 for obesity. Some clinicians and patients actually value that longer post-market surveillance window.
He also doesn't address the cardiovascular outcomes data. The LEADER trial (Marso et al., 2016, NEJM) showed liraglutide reduced major cardiovascular events in people with type 2 diabetes. That's a meaningful outcome, and dismissing liraglutide without mentioning this gives an incomplete picture for a diabetic patient audience.
His framing of liraglutide as essentially a last resort is clinically defensible but oversimplified for a general audience that may not understand why a drug with real cardiovascular benefit gets ranked last on a TikTok.
What should you actually know?
If your goal is maximizing weight loss, the data supports starting with semaglutide or tirzepatide over liraglutide, assuming access and tolerability aren't obstacles. That's not controversial at this point.
But medication choice is not just about which drug wins a head-to-head weight loss trial. Factors like insurance formularies, individual GI tolerability, injection frequency preferences, and underlying conditions all shape what the right choice actually is for a specific person. Dr. Russo nods at this with his insurance comment, but a 90-second TikTok can't fully carry that nuance.
Liraglutide is not a bad drug. It's an older drug in a class where the newer entrants have been genuinely impressive. That's a different thing. If it's what's available to you, the clinical evidence still shows meaningful metabolic and cardiovascular benefit. Anyone telling you liraglutide is useless is overselling the competition.
- Talk to a licensed provider before switching or starting any GLP-1 medication.
- Insurance coverage and prior authorization requirements vary significantly by plan and diagnosis code.
- Compounded versions of these drugs are not equivalent to FDA-approved brand-name products.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 10 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Is liraglutide actually inferior to newer GLP-1 drugs for weight loss?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Is liraglutide actually inferior to newer GLP-1 drugs for weight loss? is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
Dr.
FormBlends verdict
Dr. Russo compares liraglutide to semaglutide and tirzepatide on two dimensions: weight loss efficacy and injection frequency. The efficacy gap is well-documented in large randomized controlled trials, with liraglutide producing roughly half the percentage weight loss of semaglutide at approved obesity doses. His recommendation to reserve liraglutide for insurance-limited patients is consistent with current clinical practice patterns, though it omits liraglutide's established cardiovascular outcomes data from the LEADER trial.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Dr. Russo compares liraglutide to semaglutide and tirzepatide on two dimensions: weight loss efficacy and injection frequency. The efficacy gap is well-documented in large randomized controlled trials, with liraglutide producing roughly half the percentage weight loss of semaglutide at approved obesity doses. His recommendation to reserve liraglutide for insurance-limited patients is consistent with current clinical practice patterns, though it omits liraglutide's established cardiovascular outcomes data from the LEADER trial.
- The SCALE trial (Davies et al., 2015, The Lancet) found liraglutide 3.0 mg produced about 8% total body weight loss at one year, roughly half the result seen with semaglutide in STEP 1.
- Semaglutide 2.4 mg (Wegovy) produced 14.9% average weight loss in STEP 1 (Wilding et al., 2021, NEJM), and tirzepatide reached up to 22.5% in SURMOUNT-1 (Jastreboff et al., 2022, NEJM).
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- The SCALE trial (Davies et al., 2015, The Lancet) found liraglutide 3.0 mg produced about 8% total body weight loss at one year, roughly half the result seen with semaglutide in STEP 1.
- Semaglutide 2.4 mg (Wegovy) produced 14.9% average weight loss in STEP 1 (Wilding et al., 2021, NEJM), and tirzepatide reached up to 22.5% in SURMOUNT-1 (Jastreboff et al., 2022, NEJM).
- The LEADER trial (Marso et al., 2016, NEJM) showed liraglutide reduced major adverse cardiovascular events in type 2 diabetes patients, a data point this video skips entirely.
- Liraglutide has been on the market since 2010, giving it a longer post-market safety record than semaglutide or tirzepatide, which some providers and patients factor into treatment decisions.
- Daily injection burden is a real adherence issue. Research on GLP-1 persistence consistently shows that dosing frequency affects long-term patient compliance.
- Compounded versions of GLP-1 drugs are not FDA-approved and are not equivalent to brand-name formulations regardless of listed active ingredient.
- Any decision to start, switch, or stop a GLP-1 medication should involve a licensed prescriber who can review your full medical history, not a TikTok video.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dr. Michael Russo, MD · TikTok creator
78.5K views on this video
There are a lot of anti-diabetic medications out there, and #Liraglutide is one I don’t cover often (you may know it as Victoza or Saxenda). Here’s why it’s not what I recommend to my patients. #weightlossoc #drrusso #saxenda #weightlossmedication #diabetesmanagement #diabetesmedication #obesitymedicine
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Dr. Michael Russo, MD, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.